Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
MDxHealth ( (MDXH) ) just unveiled an announcement.
On August 5, 2025, MDxHealth agreed to acquire Exosome Diagnostics, Inc. from Bio-Techne, and the deal closed on September 15, 2025, for up to $15 million, combining stock at closing with contingent annual payments over four years, thereby adding the ExoDx test, a CLIA-certified lab and related assets to its platform. On January 9, 2026, the company also amended its GPS acquisition earnout with Exact Sciences, deferring remaining payments into 2026–2028 while issuing warrants for 3 million MDxHealth shares, moves that reshape its balance sheet and solidify its positioning in prostate cancer diagnostics despite Exosome Diagnostics’ historically loss-making profile.
Filed financial statements for Exosome Diagnostics for the year ended June 30, 2025, along with pro forma combined financial information, highlight the scale of Exosome’s operations and integration effects on MDxHealth’s results. Together, the acquisition and the revised GPS earnout schedule indicate a strategic push by MDxHealth to consolidate key prostate cancer testing assets while managing near-term cash obligations through a mix of stock consideration, structured earnouts and equity-linked instruments.
The most recent analyst rating on (MDXH) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on MDxHealth stock, see the MDXH Stock Forecast page.
Spark’s Take on MDXH Stock
According to Spark, TipRanks’ AI Analyst, MDXH is a Neutral.
MDxHealth’s overall stock score is primarily influenced by its financial performance challenges, including negative equity and cash flow issues. While the earnings call provided some positive insights into revenue growth and strategic acquisitions, the technical analysis and valuation metrics indicate bearish sentiment and financial instability. The company’s efforts to improve profitability and strategic positioning are noted, but significant risks remain.
To see Spark’s full report on MDXH stock, click here.
More about MDxHealth
MDxHealth SA is a Belgium-based molecular diagnostics company focused on urologic cancers, providing genomic and epigenetic tests to support cancer detection and treatment decisions. Its portfolio includes proprietary assays and laboratory services, and with the addition of Exosome Diagnostics’ ExoDx test and CLIA-certified lab, the group is expanding its footprint in non-invasive liquid biopsy diagnostics in the U.S. market.
Average Trading Volume: 152,505
Technical Sentiment Signal: Hold
Current Market Cap: $180.7M
Find detailed analytics on MDXH stock on TipRanks’ Stock Analysis page.